ESMO25: Transforming the cancer immunotherapy field, with Poolbeg's Liam Tremble

Poolbeg Pharma Plc is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field.

Onsite at ESMO 2025 in Berlin, pharmaphorum spoke with Liam Tremble, Principal Scientist at Poolbeg, about the company’s POLB 001 and upcoming Phase 2a clinical trial, which aims to investigate its safety and efficacy, in particular its ability to reduce the incidence of cytokine release syndrome, in approximately 30 relapsed/refractory multiple myeloma patients receiving an approved bispecific antibody. Interim data is expected in Summer 2026.

Tremble discusses their interest in the potential applicability of such treatments beyond haematological cancers and within solid tumours, as well as his hopes for oncology in the future.

Watch this and check out other conversations from ESMO 2025 here.